Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT

Rhea-AI Summary

Phio Pharmaceuticals (NASDAQ: PHIO) will present live at the Life Sciences Investor Forum on March 12, 2026 at 11:00 AM ET. CEO Robert Bitterman will review the INTASYL siRNA platform, recent clinical progress for PH-762 and host a live Q&A. Replays and 1x1 meetings are available March 16–17. The company reported Phase 1b data showing ~65% pathological response in cSCC across doses, 85% (6 of 7) at the highest dose, no dose-limiting toxicities, planned FDA engagement in Q2 2026, and cash runway into H1 2027.

News Market Reaction – PHIO

+1.65%

1 alert

+1.65% News Effect

+$228K Valuation Impact

$14M Market Cap

1K Volume

On the day this news was published, PHIO gained 1.65%, reflecting a mild positive market reaction. This price movement added approximately $228K to the company's valuation, bringing the market cap to $14M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Patients treated: 22 patients Dose-escalation cohorts: 5 cohorts Overall cSCC response: 65% pathological response +5 more

8 metrics

Patients treated 22 patients PH-762 Phase 1b trial across dose-escalation cohorts

Dose-escalation cohorts 5 cohorts PH-762 Phase 1b intratumoral trial

Overall cSCC response 65% pathological response cSCC patients across all dosing cohorts in Phase 1b

High-dose cSCC response 85% (6 of 7 patients) Highest-dose cohort pathological response in cSCC

Dose-limiting toxicities 0 observed No DLTs or serious adverse events reported in Phase 1b

FDA engagement target Q2 2026 Planned discussion on next-stage clinical development for PH-762

Cash runway Into H1 2027 Cash and cash equivalents projected to sustain operations

Investor forum time 11:00 AM ET, Mar 12, 2026 Life Sciences Investor Forum presentation

Market Reality Check

Price: $1.23 Vol: Volume 363,105 is well be...

low vol

$1.23 Last Close

Volume Volume 363,105 is well below the 20-day average of 11,001,920 (relative volume 0.03). low

Technical Shares at $1.21 are trading below the 200-day MA at $1.79, indicating a longer-term downtrend pre-event.

Peers on Argus

PHIO was up 4.31% while 3 tracked biotech peers in the momentum set (e.g., SNSE,...

3 Down

PHIO was up 4.31% while 3 tracked biotech peers in the momentum set (e.g., SNSE, BCDA, PHGE) were all moving down (median move about -1.6%), pointing to a more stock-specific move ahead of this investor forum appearance.

Historical Context

5 past events · Latest: Mar 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 05	Earnings and update	Positive	-0.8%	2025 results, PH-762 Phase 1b completion, cash of about $21M disclosed.
Mar 05	Investor presentation	Positive	+1.7%	Renmark non-deal roadshow to review INTASYL platform and PH-762 data.
Feb 19	Leadership changes	Positive	-1.7%	Key promotions and hire to support PH-762 and PH-894 development.
Feb 10	Clinical trial data	Positive	+24.4%	SMC wrap-up showing no DLTs and strong response rates for PH-762.
Jan 26	Conference participation	Positive	-4.6%	DealFlow conference presentation and Phase 1b completion reminder.

Pattern Detected

Recent PHIO news has been generally positive, but price reactions were mixed: 3 negative and 2 positive moves, indicating inconsistent follow-through even on favorable clinical and corporate updates.

Recent Company History

Over the past few months, Phio highlighted progress for lead candidate PH-762, including Phase 1b safety and efficacy signals with strong pathological responses, plus strengthened finances with $23.7M in proceeds and cash of about $21.0M at Dec 31, 2025. The company also reported leadership changes aligned to next-stage development and multiple investor conference appearances. Today’s investor forum presentation continues this outreach pattern, emphasizing the INTASYL platform and development plans following earlier Phase 1b updates.

Regulatory & Risk Context

Active S-3 Shelf · $24.5 million

Shelf Active

Active S-3 Shelf Registration 2025-11-20

$24.5 million registered capacity

An effective resale registration covers up to 11,763,800 warrant shares for selling stockholders. Phio would only receive cash if these warrants are exercised, with up to $24.5 million in potential proceeds earmarked for working capital and PH-762 development; no primary shares are being sold by the company under this prospectus.

Market Pulse Summary

This announcement highlights Phio’s upcoming Life Sciences Investor Forum presentation, where manage...

Analysis

This announcement highlights Phio’s upcoming Life Sciences Investor Forum presentation, where management plans to review the INTASYL siRNA platform and PH-762 clinical progress. It reiterates Phase 1b data showing a 65% pathological response rate in cSCC and 85% in the highest-dose cohort, alongside a projected cash runway into H1 2027. Investors may watch for added color on FDA engagement targeted for Q2 2026 and clarity on next-stage trial design and timelines.

Key Terms

sirna, gene silencing, immuno-oncology, cutaneous squamous cell carcinoma, +3 more

7 terms

sirna medical

"clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary"

Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.

gene silencing medical

"using its proprietary INTASYL gene silencing technology to eliminate cancer."

Gene silencing is a biological process that turns down or shuts off the activity of a specific gene so it stops making its product, like dimming or muting a single light in a room instead of cutting power to the whole house. Investors care because therapies or products that intentionally silence harmful genes can become new drugs, diagnostics, or royalties, affecting a company’s future revenue, risk profile, and valuation.

immuno-oncology medical

"INTASYL represents a differentiated approach to immuno-oncology and discussing our strategy"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

cutaneous squamous cell carcinoma medical

"therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma."

A common form of skin cancer that starts in the thin, outer layer of the skin and can grow or, in some cases, spread to nearby tissue or organs. For investors, it matters because diagnosis rates, available treatments, and regulatory approvals shape demand for therapies, influence clinical trial results, and affect potential revenue for companies developing drugs, devices, or diagnostics — like spotting a stubborn weed that may require different tools to remove.

merkel cell carcinoma medical

"cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma."

Merkel cell carcinoma is a rare, fast-growing form of skin cancer that starts in cells near the base of the skin and often spreads quickly to nearby tissues and organs. For investors, it matters because treatments for this aggressive disease can create high-value opportunities or risks: successful drugs or tests can unlock significant revenue and partnerships, while failed trials or regulatory setbacks can sharply affect a biotech company’s prospects — like a single critical test determining whether a new product succeeds or stalls.

pathological response medical

"reported a pathological response rate in cSCC across all dosing cohorts of approximately"

A pathological response is the change seen in tissue samples—often tumor tissue—after a medical treatment, as assessed under a microscope or by lab tests. Investors care because it provides direct evidence of whether a therapy is killing or shrinking diseased cells, acting like a close-up inspection of repairs after work is done; strong pathological responses can support regulatory approval, higher sales expectations, and a therapy’s perceived value.

phase 1b medical

"In its Phase 1b trial, Phio has reported that 22 patients completed treatment across"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

AI-generated analysis. Not financial advice.

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com

King of Prussia, Pennsylvania--(Newsfile Corp. - March 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12^th, 2026. Mr. Bitterman will provide an overview of the Company's INTASYL siRNA platform and discuss recent clinical progress and priorities, followed by a live Q&A.

"We look forward to sharing why we believe INTASYL represents a differentiated approach to immuno-oncology and discussing our strategy for PH-762 as we plan for the next stage of development," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.

DATE: March 12^th

TIME: 11:00 AM ET

REGISTER HERE

Available for 1x1 meetings: March 16^th & 17^th. Schedule 1x1 Meetings here.

The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. A replay of the webcast will be available following the conclusion of the conference.

It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.virtualinvestorconferences.com.

Recent Company Highlights

Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. The Company has also reported a pathological response rate in cSCC across all dosing cohorts of approximately 65%, including an 85% pathological response (6 of 7 patients) in the highest-dose cohort.

Phio has indicated that FDA engagement regarding next-stage clinical development is targeted for the second quarter of 2026 and has reported cash and cash equivalents projected to sustain operations into the first half of 2027.

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL^® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.

For additional information, visit the Company's website, www.phiopharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements regarding the anticipated benefits of our INTASYL™ RNAi platform, the results from our ongoing clinical trials, our expectations that our cash runway will extend into the first half of 2027, our expectations regarding timing of FDA submissions intended to propose and seek guidance for next steps in clinical study design for PH-762, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

About Virtual Investor Conferences®

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

CONTACTS:

Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs

Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/287850

FAQ

When will Phio Pharmaceuticals (PHIO) present at the Life Sciences Investor Forum?

Phio will present live on March 12, 2026 at 11:00 AM ET. According to the company, CEO Robert Bitterman will overview the INTASYL platform, discuss PH-762 clinical progress, and answer live audience questions with a replay available after the event.

What clinical results for PH-762 did Phio (PHIO) report in the Phase 1b trial?

Phio reported a ~65% pathological response in cSCC across dosing cohorts and 85% (6 of 7) at the highest dose. According to the company, 22 patients completed treatment with no dose-limiting toxicities or serious adverse events reported.

How can investors attend Phio (PHIO) presentations and schedule meetings during the forum?

Investors can register to attend the live webcast and access a replay afterward. According to the company, 1x1 investor meetings are available on March 16–17 and advance registration and system checks are recommended to participate.

What is Phio's (PHIO) near-term regulatory timeline for PH-762?

Phio targets FDA engagement in Q2 2026 regarding next-stage development of PH-762. According to the company, this engagement is intended to discuss trial design and development priorities following Phase 1b results.

What is Phio's (PHIO) reported cash runway and how long is it expected to sustain operations?

Phio reported cash and cash equivalents projected to sustain operations into the first half of 2027. According to the company, this projection reflects current resources and planned near-term clinical activities for PH-762.